THE anticoagulant rivaroxaban reduces the risk of recurrence of life-threatening blood clots more effectively than daily aspirin in patients diagnosed with venous thromboembolism, according to the double-blind, multicentre EINSTEIN CHOICE study, presented at the 66th American College of Cardiology scientific sessions.
Bayer sponsored the study.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Mar 17
